Poziotinib, an EGFR inhibitor that was previously shelved as ineffective against non–small cell lung cancer, is showing promising activity in a subset of patients with EGFR exon 20 insertions. According to preliminary data from a phase II trial, the drug led to a 73% overall response rate in patients with this disease subtype, which is typically highly resistant to standard therapy.

中文翻译：

---

Poziotinib有望治疗罕见肺癌

Poziotinib是一种EGFR抑制剂，以前被搁置为对非小细胞肺癌无效，在一部分EGFR外显子20插入患者中显示出有希望的活性。根据来自II期临床试验的初步数据，该药物导致该疾病亚型患者的总体缓解率达到73％，该患者通常对标准疗法有很高的抵抗力。